2025-05-22-Jefferies-恩哈比特（EHAB）_论文回顾运营改善_投资者关注CMS家庭健康规则_8页_129kb

Enhabit (EHAB) Healthcare Services Equity Research Summary

Analyst Recommendation

• Rating: BUY with a 12-month price target of $12.00 (+15% upside)
• Thesis: Operations are showing signs of improvement after strategic actions.
• Evidence: Reversed sequential EBITDA decline in the Home Health (HH) segment in Q1 2025, returning to ~19–20% margin profile due to improved productivity and operating leverage.
• Revenue Mix: Non-Medicare admissions grew +7.4% (lower avg. unit revenue due to shift to non-episodic volumes). Recerts declined (expected, due to strong growth cycle and shift toward earlier institutional admissions).
• G&A: Flat Y/Y; management has potential to cut costs further, supporting margin expansion.
• Catalysts: Balance sheet de-levering via potential VCG settlement/disposal OR strategic M&A ahead of the pending CMS CY26 home health reimbursement rule (likely another rate cut opportunity). Positive earnings beats contribute to building credibility.
• Market Cap: $529.8M low relative valuation which could support multiple expansion on improved performance.

Key Risks & Concerns

• Regulatory: CMS implementing a further prospective cut in CY26 home health rates (PDGM behavioral adjustment) as part of this year's rule (phased in CY25, CY26 cut still expected). Risk is compounded by market basket update uncertainty.
• Execution: Management must sustain operational improvements and deliver strong fundamentals for their growth thesis (organic growth driven by UNH contract renegotiation, favorable MA contracts, aging demographic tailwinds) to justify valuation multiple expansion.

Valuation & Growth Expectations

• Price Target: $12.00 (vs prior day's close ~$10.43)
• Base Case: Organic Rev. growth 3-5%, EBITDA growth 6-8%.
• Upside Scenario: Organic Rev. growth ~5-6%, EBITDA growth ~8-10%. Valuation 10.0x EV/EBITDA FY25E. New price target: $15.00 (+44%).
• Downside Scenario: Organic Rev. growth ~2-3%, EBITDA growth ~3-4% (incl. M&A). Valuation 7.0x EV/EBITDA FY25E. New price target: $5.00 (-53%).
• Current Multiple: ~10x EV/EBITDA (FY25E projected EBITDA: $107MM range).

This report synthesizes information from the original research note provided by Jefferies Equity Research.